Clinical trial
Daptomycin in the Treatment of Subjects With Infective Endocarditis or…
NCT00093067 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00093067 |
|---|---|
| Title | Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus |
| Official title | A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy In the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to Staph Aureus |
| Lead sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bacterial Endocarditis, Bacteremia |
| Intervention type | Drug |
| Interventions | daptomycin |
| Start date | Mar 1, 2002 |
| Primary completion | Nov 1, 2004 |
| Completion | Feb 1, 2005 |
| First posted | Oct 1, 2004 |
| Last update posted | Feb 13, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: